Pipeline

We are focused on the treatment of hemophilia using our high potency coagulation factors that promote blood clotting. A clinical trial of our Factor IX candidate in individuals with hemophilia B was initiated in June of 2017. We also plan to initiate an efficacy clinical trial of our Factor VIIa candidate in individuals with hemophilia and inhibitors in the fourth quarter of 2017.

Next Generation Hemostasis Programs

Hemophilia A or B with Inhibitors
Phase 1/2
    
Hemophilia B
Phase 1/2
    
FXa
Universal Pro-coagulant
Research
    
Drug Candidate
Indication
Research
Preclinical
Phase 1/2
Phase 2/3

*(formerly known as CB 813d)


Anti-Complement Assets

Anti-C3: CB 2782 Renal Delayed Graft Function (DGF), Ischemia/Reperfusion Injury (IRI) Cardiovascular
Anti-C3: Ophthalmic Dry Age-related Macular Degeneration (AMD)